Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Jan 21;105(10):4021–4027. doi: 10.1182/blood-2004-07-2967

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2005 by The American Society of Hematology

PMC Copyright notice

Figure 2. — Dose-dependent effect of imatinib mesylate on Akt dephosphorylation in Ba/F3p210^Bcr-Abl, Ba/F3p210^E255K, and Ba/F3p210^T315I cells. (A) Bcl-Abl expression versus phospho-Thr³⁰⁸ Akt levels in 32D, Ba/F3, Ba/F3p210^Bcr-Abl (WT), Ba/F3p210^E255K (E225K), and Ba/F3p210^T315I (T315I) cells. As shown, Akt phosphorylation is up-regulated by Bcr-Abl irrespective of mutations. (B, left) Dose-dependent effect of imatinib mesylate on Akt Thr³⁰⁸ phosphorylation (p-Thr³⁰⁸-Akt) in the 3 cell lines after 36-hour exposure. All immunoblots are representative of 3 independent experiments. (B, right) Bars represent the means of relative p-Akt level compared with the DMSO control of 3 independent determinations ± SD. According to the Jonckheere-Terpstra test, the trend P values were .004 and .022 for E225K and T315I, respectively.